ADVFN Logo ADVFN

Wir konnten keine Ergebnisse für:
Stelle sicher, dass deine Schreibweise korrekt ist oder versuche deine Suche zu erweitern.

Trends

Toplisten

Es scheint, dass du nicht eingeloggt bist.
Klicke auf den Button unten, um dich einzuloggen und deine zuletzt angesehenen Aktien zu sehen.

Registrieren

Bereits Mitglied? Einloggen

Pepperstone

Jetzt Handeln

Pepperstone
Marktdaten
News
Werkzeuge
Märkte
Entdecken

Hot Features

Follow Feed

Vernetzen Sie sich mit Händlern und Investoren in unserer Follow-Feed-Community.

Optionen-Flow

Erkunden Sie umfassende Optionsdaten und nutzen Sie erweiterte Filter mit Options Flow.

Watchlist

Organisieren und überwachen Sie Ihre Aktien- und Vermögensbeobachtungsliste mit dem Monitor.
Anmelden Premium IconPremium Help Menu
DAX
19.848,77
-0,34%
S&P 500
6.040,04
1,10%
Dow Jones
43.297,03
0,91%
Euro vs US Dollar
1,04255
0,21%
Bitcoin
98.614,75
-0,07%
Pepperstone
Advertisement
Registration Strip Icon for discussion Registrieren Sie sich, um in unseren aktiven Foren mit gleichgesinnten Anlegern zu diskutieren.
Registrieren
  1. Startseite
  2. Investieren
  3. Aktien
  4. USA
  5. NASDAQ
  6. uniQure NV (QURE)

  7. uniQure NV (QURE) News

QURE

uniQure NV (QURE)

uniQure NV
Von:
Sortieren nach:
 Showing the most relevant articles for your search:NASDAQ:QURE
DatumZeitQuelleÜberschriftSymbolFirma
10/12/202422h54Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:QUREuniQure NV
10/12/202422h33Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:QUREuniQure NV
10/12/202413h22Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:QUREuniQure NV
10/12/202413h05GlobeNewswire Inc.uniQure Announces Alignment with FDA on Key Elements of Accelerated Approval Pathway for AMT-130 in Huntington’s DiseaseNASDAQ:QUREuniQure NV
21/11/202415h00Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:QUREuniQure NV
21/11/202413h05GlobeNewswire Inc.uniQure Announces Dosing of First Patient in GenTLE Phase I/IIa Clinical Trial of AMT-260 for the Treatment of Refractory Mesial Temporal Lobe EpilepsyNASDAQ:QUREuniQure NV
14/11/202418h01Edgar (US Regulatory)Form SC 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]NASDAQ:QUREuniQure NV
05/11/202415h08Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:QUREuniQure NV
05/11/202414h02Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:QUREuniQure NV
05/11/202413h05GlobeNewswire Inc.uniQure Announces Third Quarter 2024 Financial Results and Highlights Recent Company ProgressNASDAQ:QUREuniQure NV
26/10/202403h48Edgar (US Regulatory)Form SC 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]NASDAQ:QUREuniQure NV
26/10/202403h48Edgar (US Regulatory)Form SC 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]NASDAQ:QUREuniQure NV
15/10/202413h49Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:QUREuniQure NV
15/10/202413h05GlobeNewswire Inc.uniQure Announces Dosing of First Patient in Phase I/II Clinical Trial of AMT-162 for the Treatment SOD1-ALSNASDAQ:QUREuniQure NV
23/09/202413h35Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:QUREuniQure NV
23/09/202413h05GlobeNewswire Inc.uniQure Announces Orphan Drug Designation Granted to AMT-191 for the Treatment of Fabry DiseaseNASDAQ:QUREuniQure NV
15/08/202413h48Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:QUREuniQure NV
15/08/202413h05GlobeNewswire Inc.uniQure Announces Dosing of First Patient in Phase I/IIa Clinical Trial of AMT-191 for the Treatment of Fabry DiseaseNASDAQ:QUREuniQure NV
01/08/202414h54Edgar (US Regulatory)Form S-8 - Securities to be offered to employees in employee benefit plansNASDAQ:QUREuniQure NV
01/08/202413h51Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:QUREuniQure NV
01/08/202413h43Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:QUREuniQure NV
01/08/202413h05GlobeNewswire Inc.uniQure Announces Second Quarter 2024 Financial Results and Provides Company UpdateNASDAQ:QUREuniQure NV
23/07/202413h10Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:QUREuniQure NV
23/07/202413h05GlobeNewswire Inc.uniQure Announces Closing of Sale of Manufacturing Facility to GenezenNASDAQ:QUREuniQure NV
09/07/202413h13Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:QUREuniQure NV
09/07/202413h05GlobeNewswire Inc.uniQure Announces Positive Interim Data Update Demonstrating Slowing of Disease Progression in Phase I/II Trials of AMT-130 for Huntington’s DiseaseNASDAQ:QUREuniQure NV
01/07/202413h05PR Newswire (US)Genezen to Acquire uniQure's Commercial Gene Therapy Manufacturing Operations in Lexington, MANASDAQ:QUREuniQure NV
01/07/202413h05GlobeNewswire Inc.uniQure Announces Sale of Commercial Manufacturing Facility to GenezenNASDAQ:QUREuniQure NV
20/06/202414h53Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:QUREuniQure NV
20/06/202414h49Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:QUREuniQure NV
 Showing the most relevant articles for your search:NASDAQ:QURE

Kürzlich von Ihnen besucht

COIN
AVAXUSD
Avalanche
USOTC
BASFY
BASF (QX)
TG
D7G
Nel ASA
TG
432
Arbor Metals
NYSE
DIS
Walt Disney
TG
DBK
Deutsche Bank
NYSE
XOM
Exxon Mobil
AMEX
XLV
Health Care Select Sector
NASDAQ
MSFT
Microsoft
TG
NOV
Novo Nordisk
USOTC
BNPQY
BNP Paribas (QX)
AMEX
SPY
SPDR S&P 500
NYSE
NKE
Nike
USOTC
RHHBY
Roche (QX)
CCOM
US30
US 30
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

Deutschland
Unternehmen
Geschäft
Popular
App herunterladen
App Store
Google Play

Support: +44 (0) 203 8794 460 | support@advfn.de

Durch das Benutzen des ADVFN Angebotes akzeptieren Sie folgende Allgemeine Geschäftsbedingungen

© 2024 ADVFN PLC - Alle Rechte vorbehalten